Zacks: Analysts Expect Zynex Inc. (NYSE:ZYXI) Will Post Quarterly Sales of $17.62 Million

Equities analysts expect that Zynex Inc. (NYSE:ZYXI) will post $17.62 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Zynex’s earnings. The lowest sales estimate is $17.50 million and the highest is $17.80 million. Zynex reported sales of $10.30 million in the same quarter last year, which indicates a positive year over year growth rate of 71.1%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Zynex will report full-year sales of $79.92 million for the current year, with estimates ranging from $77.73 million to $81.52 million. For the next year, analysts forecast that the firm will post sales of $126.65 million, with estimates ranging from $105.00 million to $138.30 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Zynex.

Zynex (NYSE:ZYXI) last posted its earnings results on Tuesday, April 28th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. The firm had revenue of $15.23 million during the quarter, compared to analyst estimates of $15.07 million.

Separately, HC Wainwright lowered shares of Zynex from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 19th.

NYSE:ZYXI traded up $1.46 during midday trading on Friday, reaching $24.64. The stock had a trading volume of 433,573 shares, compared to its average volume of 684,271. Zynex has a 1-year low of $7.12 and a 1-year high of $27.00. The firm’s fifty day simple moving average is $21.17 and its 200-day simple moving average is $13.66.

Zynex Company Profile

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device.

Recommended Story: The primary rules of Elliott Wave theory

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with's FREE daily email newsletter.